263 filings
8-K
EPIX
Essa Pharma Inc
14 May 24
Results of Operations and Financial Condition
7:01am
10-Q
2024 Q2
EPIX
Essa Pharma Inc
Quarterly report
14 May 24
7:00am
S-8
EPIX
Essa Pharma Inc
5 Apr 24
Registration of securities for employees
4:57pm
8-K
EPIX
Essa Pharma Inc
7 Mar 24
Submission of Matters to a Vote of Security Holders
5:18pm
10-Q
2024 Q1
EPIX
Essa Pharma Inc
Quarterly report
13 Feb 24
7:01am
8-K
87h3ba9q8bdomp70f
13 Feb 24
Results of Operations and Financial Condition
7:01am
8-K
v1lz0s46
29 Jan 24
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium
9:15am
DEFA14A
00co23aj3g zryy3ye0u
26 Jan 24
Additional proxy soliciting materials
4:40pm
8-K
8uik19y 3wkj
12 Dec 23
Results of Operations and Financial Condition
7:01am
8-K
600qie75s0ydv2 ahm
6 Nov 23
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement
4:57pm
424B5
l47uep5vsf583r8h
3 Nov 23
Prospectus supplement for primary offering
9:44pm
8-K
8hcbezf
26 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat
8:07pm
8-K
1ps85h
23 Oct 23
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 Congress
4:19pm
EFFECT
itb36ygw
11 Oct 23
Notice of effectiveness
12:15am
CORRESP
qoyfzbxqxiefn6ffu0e
6 Oct 23
Correspondence with SEC
12:00am
CORRESP
o4eo8i0xhz
6 Oct 23
Correspondence with SEC
12:00am
CORRESP
ygoyp
3 Oct 23
Correspondence with SEC
12:00am